As the Antibody-Drug Conjugate (ADC) market continues to expand, developers face increasing scientific, operational, and manufacturing complexity across the ADC lifecycle. Bringing these highly complex molecules from concept to commercialization requires not only specialized technical expertise, but also close integration across development and manufacturing stages.
An integrated ADC approach can simplify development pathways, reduce handoffs between vendors, and support more efficient progression from preclinical studies through commercial supply. This webinar explores the benefits of an end-to-end ADC model, including how coordinated development, scalable manufacturing strategies, and lifecycle oversight can help mitigate risk, accelerate timelines, and support consistent product quality.
Drawing on Lonza’s experience supporting ADC programs across multiple stages of development and commercialization, the session also shares practical insights into how integrated capabilities are applied in real-world ADC manufacturing and how they can be leveraged to support long-term program success.
